Vartelus, Innovative Disruption for Better Health Outcomes.



Vartelus combines the latest and leading Digital Human and Conversational AI Technologies from AWS, Microsoft, Google and more, specifically designed for the life science industry; it is set to lead the evolution of patient and physician engagement, driving better health outcomes.


Our technology is leading the evolution of healthcare professional (HCP) and patient engagement by combining medically approved information, qualified real-life experience, and brand strategies to provide HCPs and patients with on-demand 100% compliant, consistent, and unlimited conversation and information, 24/7. 


Vartelus is designed to give HCPs confidence in prescribing medications, and to support patients in combatting non-compliance, resulting in better patient outcomes and increased market share for pharma companies.


What's more, Vartelus is designed to augment human roles and we believe will ultimately protect jobs.


Digital

Human

Insourcing

Solutions

for

Life Science

Digital Human Insourcing Solutions

for Life Science

“Some challenges haven't changed!”


A challenging introduction by Graham Wilson, Chairman of Ecoutai Limited


It’s 37 years since, as a founder of Innovex [Quintiles] we disrupted the industry, yet I still hear the same industry challenges and read about the same regurgitated solutions – we’re still not evolving fast enough!

 

Having just lost access to 50% of the HCP audience who won't see pharma reps post the Covid-19 era, plus reducing sales teams and low contact rates, the industry is struggling to maintain and increase sales and market share. Yet they still seem to do more of the same with less people. Ineffective omnichannel strategies, that everyone uses, simply drown HCPs with a multitude of information that is just too much for HCP's! 

 

Let’s also consider patient noncompliance, which costs the global pharma industry around $630bn a year, the NHS around £800M, and the USA health systems around $250bn. We call it the forever problem it's been around so long so WHY has this not been addressed? When trying to sell more is harder, change the model, and consider the increase in lifetime brand value by improving compliance. With technology we can address this.

 

This lack of innovation is just making it harder for everyone and by the time it doesn't deliver, the problem is even bigger. So, let's look differently at the problem, and explore a better way to grow your business, and protect people and reinvestment in future development. Stand out from the crowd!

 

With technology we change that for the good of all…

 

Best wishes,

Graham.

Invest

The Forever Problems

Non-Compliance

Is a global issue


50% of patients don’t complete prescribed drug courses or take them properly

Time Constraints

Doctors don’t have the time to educate patients

6 minutes with a doctor doesn’t change behaviour

Poor compliance = Poor outcomes

The Cost?

Non-compliance costs pharma $630bn per annum


Non-compliance costs the NHS £500–800m and US health systems $250bn per annum.

Competition

Competition for sales is high,

a doctor has over

3,000 drug choices

More about us
  • “This looks like the Sales rep/MSL of the future”

    Head of Medical Information and Digital Innovation top 5 Pharma Co

    Button
  • “We don’t have enough time to fully explain products, so compliance remains poor”

    Associate professor, GP, Cardiology specialist, Research team lead

    Button
  • “This is the right way to interact for the future”

    Professor of Cardiology, Clinical Research Lead, KOL to 7 top Pharma Co’s and Tech advisor

    Button

Introducing Rebecca

 Read our blog

By Ian Welburn 03 Oct, 2023
Innovation Recent technology advances include pioneering work using a unique combination of digital human and conversational AI technologies to enable patients to access the information and support they need about medications to reduce poor adherence and thereby optimise health outcomes. Additionally, Clinicians can have scientific and medical discussions, and access information about pharmaceutical products to drive their confidence to prescribe those medications. It should be noted that the use of AI discussed here is within conversational technology and not the collection of big data, which is a common misunderstanding. Why life science needs to embrace this technology… Pharma needs innovative ways to maintain and ideally increase contacts with Clinicians. Pharma continues to push for more sales at a time when access to their target audience is halved, and many Pharma Cos are reducing sales team numbers. Market share remains a key metric for Pharma and declining contact with their audience is a problem yet to be solved. Innovation offers a way to increase touch points and augment the role of existing sales, medical, and support teams. Clinicians expect to operate differently via online options and at times to suit them; a rep can’t call at 6.00am or 11.00pm. The model has changed. Coverage of Clinicians with new information has always been slow; technology offers the fastest option ever to contact Clinicians re: product updates and changes – a ‘product launch on overdrive’! Pharma will want to drive patient adherence to their medications; this technology can deliver that, and patients will engage, resulting in better health outcomes, For many patients a prescription is only part of the solution, and a behavioural change is essential for best outcomes; this technology can proactively engage patients to support, educate and reassure. Analytics are not designed to compete with the plethora of existing major providers; however, they can offer immediate feedback on key aspects of any Clinician engagement, with reference to reaction to the product and competition, and other core medical data such as prescribing habits and dosages. This will be unique data, relevant to the reality of Clinician practice. The pharma sales model needs to change from “Push to Pull” engagement. This technology enables a new level of engagement that the Clinician can feel more in control of. This can also be extended to other professionals within the Clinician practice, thus building new communities to embrace the brands. Engagement with Clinicians can be further enhanced through offering links to educational and patient focussed information when appropriate. Brand loyalty can be enhanced by enabling Clinicians to offer better support to patients; it can improve outcomes and reduce unnecessary, and time consuming, visits by answering common questions and dealing with concerns. This technology enables unlimited access for Clinicians and provides infinite accessibility for patients. This technology is ‘life science ready’ which means it will always be 100% compliant and consistent for legal and data requirements – something never achieved before or available via generally available conversational technologies. Importantly for pharma and med tech, this technology delivers consistency of messaging and enables Clinicians and patients to access the information they need 24/7, essential for worried patients. The technology will help to change behaviours, particularly patients, regarding their understanding of the reasons for taking a medication correctly and completely, resulting in improved adherence which will have a significant positive impact on health system costs globally. Summary : Access to customer groups is in significant decline and yet the need is there for education and support for Clinicians in the use and understanding of prescribed medications. Pharma is constantly searching for alternate ways to engage with Clinicians to protect brand revenues and now proactively promote to patients to improve health outcomes. Author: Ian Welburn Date: 2nd October 2023 Email: ian.welburn@ecoutai.net
17 Apr, 2023
The age-old problem of patient non-compliance, which costs the global pharmaceutical industry $630 billion per annum, the NHS around £500 to £800 million per annum, and the US health systems $250 billion per annum, has never been solved by human only means. It is now time to augment human activities using the latest technology solutions, available to life science and healthcare for the first time. Why do patients not take their medication correctly? Physicians don’t have time to educate patients, and many don’t have the communication skills to achieve this; in the average 6-minute consultation, patient behaviour doesn’t change plus it’s more difficult to see physicians post Covid-19. A staggering 50% of patients don’t complete prescribed drug courses or take them properly. Not only does this patient non-compliance seriously affect health outcomes, it also significantly reduces the lifetime value of brands. While market share remains even harder to grow and is complicated by a declining available audience, consider what is lost though non-compliance and how reducing that decline can have a huge effect on market shares. The more the patient understands, the better the outcome. One of the main factors to better patient compliance and outcomes is for the patient to fully understand why they have been prescribed a particular product or medical device, and what it will achieve for them. They also need to be competent in how to take the medication and confident that, whatever the journey, for example side effects, they will achieve the best results by taking the full course of prescribed medication in the right way. Additionally, for a patient to have a good grasp of the disease/therapy area from medically approved sources, the better their understanding and belief in the treatment. The best patient outcomes are about behaviour. Digital Humans enable patients to understand and learn new behaviours, which for many with chronic conditions cannot be overlooked, for example, a newly diagnosed diabetic or asthmatic faces a huge ‘life change’ and in the typical 6 minutes they have with a physician, are very unlikely to understand what it all means. Patient’s minds are in a state of concern, even panic, considering all the negative views and often differing opinions they may have read on the internet. They have medical support brochures of course, but with an average reading age of 9 in the UK and United States for example, many will not understand even the basic medical content. It can take many weeks or months to change a lifetime of certain behaviours, and frequent returns to their doctor or nurse for more advice is a frustration for everyone, more so with post-covid-19 appointment issues. Even at follow-up appointments, some patients will not ask the right questions, for example “will I put on weight if I take this?” or “will it affect my sex drive?”. Questions like that, if left unanswered, will likely increase the risk of non-compliance. We must further consider the negative effects of internet blogs by unqualified ‘lay people’ that can undermine approved clinical information. We see more and more unqualified ‘influencers’ making claims that have no clinical basis or evidence; these claims worry patients with dis-information. Pharma and healthcare providers need to protect against this to ensure the patient gets the full and honest facts, based on 10-15 years of research that will enable most patients to have successful outcomes through full compliance. Helping patients achieve better health outcomes. Digital Human technology is designed to improve patient outcomes by significantly reducing patient non-compliance to prescribed medication. The technology enables patients to access comprehensive, understandable, compliant, and consistent information, conversation, and support, on demand 24/7 about products and therapy areas, so that they understand the importance of taking the full course of medication and how to take it properly. This technology is reactive by answering patient questions and offering them access to educational support, but also ‘proactively’ connecting with the patient on a prescribed number of occasions to see how they are progressing, helping them understand better, and answering any questions or concerns. So how can we achieve the best health outcomes? Let’s not keep doing want we’ve always done – the technology innovation to help is here now – Science Fact not Fiction! Ian Welburn is Founder and CEO of Ecoutai Limited.
Show More
Share by: